Granite FO LLC’s GSK GSK Stock Holding History

Granite FO LLC’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,664	Closed	-$60K	–	189
2023 Q1	$60K	Buy	+1,664	New	+$58.2K	0.04%	144

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Granite FO LLC's GSK Position: Q2 2023 in Review

Granite FO LLC sold out of GSK (GSK) in Q2 2023, closing a stake of 1,664 shares — an estimated $60K sold.

Granite FO LLC first reported a position in GSK in Q1 2023 and held it in 1 quarter. The position peaked at $60K in Q1 2023. 827 funds tracked by Wall St. Rank hold GSK as of Q2 2023.

Granite FO LLC reported no remaining GSK position as of Q2 2023 after selling out during the quarter.
Granite FO LLC sold 1,664 GSK shares in Q2 2023, an estimated $60K.
Granite FO LLC first reported a position in GSK in Q1 2023 and held it in 1 quarter.
Granite FO LLC's GSK position peaked at $60K in Q1 2023.
827 funds tracked by Wall St. Rank held GSK as of Q2 2023.

Based on Granite FO LLC's 13F filing for Q2 2023, filed 5 Sep 2024.